Literature DB >> 20192711

Updated vaccine guidelines for aging and aged citizens of Europe.

Jean-Pierre Michel1.   

Abstract

There is a high burden of infectious diseases in the older population, which is associated with increased morbidity and mortality compared with younger age groups. Too many of these diseases are vaccine preventable yet there is a low vaccine coverage rate across Europe. These findings led the European Union Geriatric Medicine Society and the International Association of Gerontology and Geriatrics-European Region to convene an expert Working Group to address the issue of why vaccination programs have failed to provide adequate protection in older European populations and to recommend immunization guidelines to ensure that they contribute to a healthy aging strategy. This review addresses some of the main issues relating to poor vaccine uptake in older adults and presents the recommendations of the joint Working Group regarding the optimal use of the following vaccines: tetanus-diphtheria-pertussis, influenza, pneumococcal (PV23) and herpes zoster. To improve vaccine coverage, communication and awareness of vaccine preventable diseases in the general community is an important starting point, and all healthcare professionals and public health/social workers can play a key role in this regard.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20192711     DOI: 10.1586/erv.10.27

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  6 in total

Review 1.  Vaccination in the elderly: what can be recommended?

Authors:  Pierre-Olivier Lang; Richard Aspinall
Journal:  Drugs Aging       Date:  2014-08       Impact factor: 3.923

2.  Strategies in recommending influenza vaccination in Europe and US.

Authors:  Caterina Rizzo; Giovanni Rezza; Walter Ricciardi
Journal:  Hum Vaccin Immunother       Date:  2018-01-09       Impact factor: 3.452

3.  Evaluation of adult dTPaP vaccination coverage in France: experience in Lyon city, 2010-2011.

Authors:  Dominique Baratin; Corinne Del Signore; Jacques Thierry; Evelyne Caulin; Philippe Vanhems
Journal:  BMC Public Health       Date:  2012-11-01       Impact factor: 3.295

4.  Immunogenicity and safety results from a randomized multicenter trial comparing a Tdap-IPV vaccine (REPEVAX®) and a tetanus monovalent vaccine in healthy adults: new considerations for the management of patients with tetanus-prone injuries.

Authors:  Henri Laurichesse; Ulrich Zimmermann; Florence Galtier; Odile Launay; Xavier Duval; Patrick Richard; Christine Sadorge; Benoit Soubeyrand
Journal:  Hum Vaccin Immunother       Date:  2012-10-02       Impact factor: 3.452

5.  What are the most important infectious diseases among those ≥65 years: a comprehensive analysis on notifiable diseases, Norway, 1993-2011.

Authors:  Anneke Steens; Hanne-Merete Eriksen; Hans Blystad
Journal:  BMC Infect Dis       Date:  2014-02-04       Impact factor: 3.090

Review 6.  The sustainability of influenza vaccination programs: considerations and perspectives from Italy.

Authors:  A Poscia; J Stojanovic; W Ricciardi
Journal:  J Prev Med Hyg       Date:  2016
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.